| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/18/2001 | CA2321437A1 Dna encoding structural protein-1 of infectious salmon anaemia virus and uses thereof |
| 04/17/2001 | US6218596 Enhancement of musculature in non-human mammals expressing c-ski |
| 04/17/2001 | US6218529 Nucleotide sequences; for the detection and treatment of tumors |
| 04/17/2001 | US6218528 MurB |
| 04/17/2001 | US6218511 Anti-apoptotic genes of human cytomegalovirus (HCMV) and their use |
| 04/17/2001 | US6218372 Methods for treating restenosis with p21 |
| 04/17/2001 | US6218370 Useful for cell transfection |
| 04/17/2001 | US6218187 Infect human stem cells with microoganism supernatant; transfect cells, separate cells from supernatant, add adhesion molecules to culture plates, propagate second group of cells with supernantant and recover transduced cells |
| 04/17/2001 | US6218186 HIV-MSCV hybrid viral vector for gene transfer |
| 04/17/2001 | US6218181 Retroviral packaging cell line |
| 04/17/2001 | US6218180 Virion coding a toxic agent, cytokine and tumor suppressor; for the treatment of tumorous defects; antitumor agents |
| 04/17/2001 | US6218179 Nucleotide sequences coding human metallothionein regulatory sequences; for reducing ischemic injury to a cell exposed to hypoxic conditions |
| 04/17/2001 | US6218159 Amino acid sequence; bacteriostats; bactericides; antibiotics; diagnosis of infections; drug screening |
| 04/17/2001 | US6218148 DNS encoding stem cell factor |
| 04/17/2001 | US6218120 Methods for detecting human methylene tetrahydrofolate reductase allelic variants |
| 04/17/2001 | US6218112 Screening peptides for ability to transfect cells with nucleic acid by detecting change in surface plasmon resonance caused by binding/dissociation of peptide to nucleic acid immobilized on sensor chip, calculating equilibrium constant |
| 04/17/2001 | US6217912 Polyester analogue of poly-L-lysine as a soluble, biodegradable gene delivery carrier |
| 04/17/2001 | US6217900 Vesicular complexes and methods of making and using the same |
| 04/17/2001 | US6217869 Administering antibody, antigen, ligand complex |
| 04/17/2001 | US6217861 pneumococcus; use as drug target for drug screening antibiotics |
| 04/17/2001 | US6217860 Supplying adenoviral vector into tumor |
| 04/17/2001 | US6217859 Orally administering genetic engineered bacteria |
| 04/17/2001 | CA2071483C Oligonucleotide analogs with novel linkages |
| 04/12/2001 | WO2001025489A2 Diagnostic and therapeutic uses for a gene differentially expressed in prostate cancer |
| 04/12/2001 | WO2001025466A1 Producer cell for the production of retroviral vectors |
| 04/12/2001 | WO2001025465A1 Adeno-associated viruses and uses thereof |
| 04/12/2001 | WO2001025464A1 Materials and methods for simplified aav production |
| 04/12/2001 | WO2001025462A1 Production of recombinant aav using adenovirus comprising aav rep/cap genes |
| 04/12/2001 | WO2001025461A1 Utrophin gene promoter |
| 04/12/2001 | WO2001025452A1 Targeted gene therapy |
| 04/12/2001 | WO2001025450A1 Use of soluble costimulatory factor for tumor immuno-gene therapy |
| 04/12/2001 | WO2001025446A1 Dna encoding prost 07 polypeptide |
| 04/12/2001 | WO2001025442A1 Dna polymerase lambda and uses thereof |
| 04/12/2001 | WO2001025441A2 Tumour-specific vector for gene therapy |
| 04/12/2001 | WO2001025438A2 Ifn-alpha homologues |
| 04/12/2001 | WO2001025437A2 Growth factor polypeptides and nucleic acids encoding same |
| 04/12/2001 | WO2001025436A2 Endozepine-like polypeptides and polynucleotides encoding same |
| 04/12/2001 | WO2001025435A2 In vivo treatment of joint disease using interleukin-1 receptor antagonists |
| 04/12/2001 | WO2001025434A1 G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| 04/12/2001 | WO2001025433A2 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 04/12/2001 | WO2001025427A1 Shear stress-response dna |
| 04/12/2001 | WO2001025422A2 Antisense compositions and cancer-treatment methods |
| 04/12/2001 | WO2001025419A1 ALTERING GENE EXPRESSION WITH ssDNA PRODUCED IN VIVO |
| 04/12/2001 | WO2001025415A2 Gene transfer in human lymphocytes using retroviral scfv cell targeting |
| 04/12/2001 | WO2001025409A1 Novel human lipase proteins, nucleic acids encoding them, and uses of both of these |
| 04/12/2001 | WO2001025408A1 Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof |
| 04/12/2001 | WO2001025398A2 Process for inducing functional tolerance to gene transfer products |
| 04/12/2001 | WO2001025397A2 Compositions and methods for tumor-targeted delivery of effector molecules |
| 04/12/2001 | WO2001025271A2 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 04/12/2001 | WO2001025269A2 Human g-protein coupled receptor |
| 04/12/2001 | WO2001025252A1 Tissue plasminogen activator-like protease |
| 04/12/2001 | WO2001025248A2 Design of high affinity rnase h recruiting oligonucleotide |
| 04/12/2001 | WO2001024832A2 Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof |
| 04/12/2001 | WO2001024821A1 Nell-1 enhanced bone mineralization |
| 04/12/2001 | WO2001024820A1 Fusion proteins of mycobacterium tuberculosis |
| 04/12/2001 | WO2001024819A1 YsxC |
| 04/12/2001 | WO2001024815A1 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 04/12/2001 | WO2001024774A1 Ortho ester lipids |
| 04/12/2001 | WO2001024773A1 Liposome-entrapped dna oral vaccines |
| 04/12/2001 | WO2001024764A2 Cell targeting compositions and methods of using the same |
| 04/12/2001 | WO2001024684A2 Methods for treatment of solid tumors and metastasis by gene therapy |
| 04/12/2001 | WO2000077190A3 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt |
| 04/12/2001 | WO2000074723A3 Methods for the gene therapy of benign prostatic hyperplasia and medical agents therefore |
| 04/12/2001 | WO2000069454A8 Suppression of endogenous igfbp-2 to inhibit cancer |
| 04/12/2001 | WO2000065063A3 Nucleic acid vaccines against rickettsial diseases and methods of use |
| 04/12/2001 | WO2000049166A3 Production of helper dependent adenovirus vectors based on use of endonucleases |
| 04/12/2001 | WO2000006199A8 Kvlqt1 - a long qt syndrome gene |
| 04/12/2001 | WO1999051735A3 Mapkap kinase 2-inhibitors and the use thereof in anti-inflammatory therapy |
| 04/12/2001 | WO1999050284A3 Nucleic acid molecules which code proteins influencing bone development |
| 04/12/2001 | US20010000228 Use of a modified baculovirus containing exogenous nucleic acid for the manufacture of a medicament for delivering said nucleic acid to the hepatocytes |
| 04/12/2001 | CA2388864A1 Ortho ester lipids |
| 04/12/2001 | CA2388533A1 Utrophin gene promoter |
| 04/12/2001 | CA2388487A1 Tissue plasminogen activator-like protease |
| 04/12/2001 | CA2386841A1 Fusion proteins of mycobacterium tuberculosis |
| 04/12/2001 | CA2386722A1 Materials and methods for simplified aav production |
| 04/12/2001 | CA2386546A1 Adeno-associated viruses and uses thereof |
| 04/12/2001 | CA2386533A1 Use of soluble costimulatory factor for tumor immuno-gene therapy |
| 04/12/2001 | CA2386465A1 Compositions and methods for tumor-targeted delivery of effector molecules |
| 04/12/2001 | CA2386383A1 Growth factor polypeptides and nucleic acids encoding same |
| 04/12/2001 | CA2386377A1 Cell targeting compositions and methods of using the same |
| 04/12/2001 | CA2386374A1 Methods for treatment of solid tumors and metastasis by gene therapy |
| 04/12/2001 | CA2386246A1 Altering gene expression with ssdna produced in vivo |
| 04/12/2001 | CA2386199A1 Endozepine-like polypeptides and polynucleotides encoding same |
| 04/12/2001 | CA2386024A1 Liposome-entrapped dna oral vaccines |
| 04/12/2001 | CA2385853A1 Design of high affinity rnase h recruiting oligonucleotide |
| 04/12/2001 | CA2385823A1 Production of recombinant aav using adenovirus comprising aav rep/cap genes |
| 04/12/2001 | CA2385703A1 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 04/12/2001 | CA2385220A1 Antisense compositions and cancer-treatment methods |
| 04/12/2001 | CA2385127A1 Novel hepatoma-derived growth factor-like proteins, polynulceotides encoding them and methods of use |
| 04/12/2001 | CA2385045A1 Ifn-alpha homologues |
| 04/12/2001 | CA2385032A1 G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| 04/12/2001 | CA2384696A1 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 04/12/2001 | CA2382859A1 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 04/12/2001 | CA2379462A1 Human g-protein coupled receptor |
| 04/11/2001 | EP1091000A1 An attenuated vaccination and gene-transfer virus, a method to make the virus and a pharmaceutical composition comprising the virus |
| 04/11/2001 | EP1090990A1 Human g-protein-coupled receptor |
| 04/11/2001 | EP1090989A1 Human g-protein-coupled receptor |
| 04/11/2001 | EP1090985A1 Feline-derived T-cells |
| 04/11/2001 | EP1090926A1 Human G-protein coupled receptor |
| 04/11/2001 | EP1090925A1 Human G-protein coupled receptor |